By continuing to use our site, you agree to our Terms of Use and Privacy Policy. You can learn more about how we use cookies by reviewing our Privacy Policy.

I Agree

About Carl Langren:

Carl Langren is the Chief Financial Officer of Lumos Pharma. He brings over 13 years of public company executive experience in biotechnology, including finance, federal contracting, information systems, compliance, and operations. Prior to the merger with Lumos Pharma, he served as the Chief Financial Officer at NewLink Genetics Corporation. Mr. Langren has enjoyed a career in management and finance that has included positions in venture capital, manufacturing, distribution and public accounting.

Mr. Langren joined NewLink Genetics in 2011 and served as Vice President, Finance until his promotion to Chief Financial Officer in 2018. Prior to NewLink, Mr. Langren was the Chief Financial Officer of BioProtection Systems Corporation, a wholly owned subsidiary of NewLink Genetics. BioProtection Systems focused on the research, development and commercialization of vaccines to control the spread of emerging infectious diseases, improvement in the efficacy of existing vaccines and providing rapid-response prophylactic and therapeutic treatment for pathogens most likely to enter the human population through pandemics or acts of bioterrorism.

Prior to BioProtection Systems, Mr. Langren was Chief Financial Officer of Housby Mixer Group, where he managed financial development and the creation of an e-commerce system for a three-tier distribution channel. Before that, as President of Iowa Machinery and Supply, a distribution company, he facilitated a fivefold increase in equity and near doubling of revenues by focusing on customer needs, reorganizing operating divisions and expanding geographic coverage.

Mr. Langren began his career as an auditor at McGladrey. Mr. Langren received a BA in accounting, with highest distinction, from the University of Iowa.